Akèy › Limfòm Non-Hodgkin
Etid klinik pou Limfòm Non-Hodgkin ap rekrite nan Etazini
127 etid pou Limfòm Non-Hodgkin ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX31 etid
- New York City, NY31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Atlanta, GA18 etid
- Chicago, IL18 etid
- Columbus, OH18 etid
- Milwaukee, WI18 etid
- Washington, DC18 etid
- Dallas, TX17 etid
- Durham, NC16 etid
- Seattle, WA16 etid
- Portland, OR15 etid
- Rochester, MN14 etid
- Miami, FL14 etid
- Omaha, NE14 etid
- Denver, CO14 etid
- Cleveland, OH13 etid
- Salt Lake City, UT13 etid
- Mountain View, CA12 etid
- St. Louis, MO11 etid
- Aurora, CO11 etid
- Los Angeles, CA9 etid
- Tampa, FL9 etid
- Jacksonville, FL9 etid
- Cincinnati, OH9 etid
- San Francisco, CA9 etid
- Pittsburgh, PA8 etid
- San Diego, CA8 etid
- Baltimore, MD8 etid
- Ann Arbor, MI8 etid
- Cedar Rapids, IA8 etid
- Clifton, NJ7 etid
- Buffalo, NY7 etid
- Kansas City, MO7 etid
- Edison, NJ7 etid
- Birmingham, AL7 etid
- Queens, NY7 etid
Pa eta
- Alabama7 etid
- Arizona14 etid
- Arkansas5 etid
- Ayiti3 etid
- Colorado20 etid
- Connecticut8 etid
- Delaware4 etid
- Distrik Columbia4 etid
- Florid32 etid
- Georgia21 etid
- Idaho3 etid
- Illinois20 etid
- Indiana10 etid
- Iowa10 etid
- Kalifòni42 etid
- Kansas9 etid
- Kentucky5 etid
- Lwizyàn6 etid
- Main4 etid
- Maryland21 etid
- Massachusetts28 etid
- Michigan13 etid
- Minnesota19 etid
- Mississippi3 etid
- Missouri10 etid
- Montana3 etid
- Nebraska15 etid
- New Jersey13 etid
- New Mexico4 etid
- New York40 etid
- North Carolina24 etid
- North Dakota3 etid
- Ohio34 etid
- Oklahoma3 etid
- Oregon15 etid
- Pennsylvania26 etid
- Rhode Island5 etid
- South Carolina5 etid
- South Dakota3 etid
- Tennessee24 etid
- Texas48 etid
- Utah14 etid
- Virginia13 etid
- Washington20 etid
- West Virginia3 etid
- Wisconsin20 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT01853631Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT02917083Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07763210A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07582432T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05645107NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07052305A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT02682667Tissue Collection for Studies of Lymph Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT01676805Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT03223610A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07519772Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 25, 2026 · NCT05907759Epco, Zanu, Ritux for R/R FL or MZL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04002947Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Sep 15, 2026 · NCT05798897Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.